RSA is pleased to announce the placement of Jack Talley as President and Chief Executive Officer of Actinium Pharmaceuticals, Inc.
The placement of pharmaceutical industry veteran Jack Talley successfully concludes RSA’s Executive Search. Hired by Actinium, RSA was tasked with finding a seasoned executive to strengthen its senior management team as the company prepares to raise additional capital and list on the public stock markets later this year.
A private biopharmaceutical company, Actinium develops innovative targeted radio-immunotherapeutics to treat various cancers. With more than 30 years of experience in marketing, drug development and regulatory matters, Jack proved the perfect candidate at this pivotal moment in the Company’s history.
Sandesh Seth, a Board Member of Actinium says “We are very pleased to have Jack Talley on board as our new CEO. RSA did an outstanding job and we would like to thank them for their professional approach in delivering a truly excellent result.”